Navigation Links
Sinovac Announces Closing of Common Share Offering
Date:2/2/2010

BEIJING, Feb. 2 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ( SVA) ("Sinovac" or the "Company"), a leading China-based vaccine manufacturer, announced today that its previously announced public common share offering was closed on February 2, 2010. Sinovac received net proceeds of approximately $62.0 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, which included net proceeds from the sale of 1,500,000 common shares pursuant to the full exercise of the underwriters' over-allotment option.

UBS Securities LLC and Piper Jaffray & Co. served as joint bookrunners for the offering.

The offering was made under Sinovac's currently effective shelf registration statements on Form F-3 filed with the Securities and Exchange Commission on November 18, 2009 and January 27, 2010. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, securities, and does not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from UBS Securities LLC, Attention: Prospectus Department, 299 Park Avenue, New York, NY 10171, U.S.A., telephone: 888-827-7275, or Piper Jaffray & Co., Attention: Equity Capital Markets, 800 Nicollet Mall, Suite 800, Minneapolis MN 55402, U.S.A., telephone: 1-800-754-4781.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(R) and Panflu.1(TM), Sinovac's pandemic influenza vaccine (H5N1) and H1N1 vaccine, have already been approved for government stockpiling. Sinovac is developing vaccines for a number of different infectious diseases including enterovirus 71, pneumococcal disease, Japanese encephalitis, haemophilus influenzae type b (Hib), meningitis, rabies, chickenpox, mumps and rubella. Sinovac is also conducting field trials for independently developed inactivated animal rabies vaccine.

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in its expectations, except as may be required by law.

    For further information, please contact:

    Sinovac Biotech Ltd.
     Helen G. Yang
     Tel:   +86-10-8289-0088 x9871
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
    The Ruth Group
     Amy Glynn/Stephanie Carrington
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
    The Ruth Group
     Janine McCargo
     Tel:   +1-646-536-7033
     Email: jmccargo@theruthgroup.com

SOURCE Sinovac Biotech Ltd.


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Sinovac Announces Exercise of Over-Allotment Option
2. Sinovac Obtains Second Order of H1N1 Vaccine from Chinese Central Government
3. Sinovac Announces Supply Agreement with Boryung Pharmaceutical Company Limited in South Korea
4. Sinovacs H1N1 Vaccine Passes Experts Evaluation Organized by SFDA
5. Sinovac Wins Beijing Public Health Bureaus Bid to Supply Seasonal Flu Vaccine Anflu(R) to Beijing Citizens
6. Sinovac Reports Unaudited Second Quarter 2009 Financial Results
7. Sinovac Schedules 2008 Annual General Meeting
8. Sinovac Reports Unaudited First Quarter 2009 Financial Results
9. Sinovac Announces that Government Investigation Rules Out Healives Role in Childs Death
10. Sinovac Provides Support to Chinas Ministry of Health to Aid Earthquake Victims
11. Sinovac to Present at the Brean Murray, Carret & Co. Fourth Investor Tour of China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... Tiny Transitions ( tinytransitions.com ), ... in-home and online newborn sleep consultations . , “We are seeing now, ... company owner Courtney Zentz, a pediatric sleep professional, post-partum doula and certified lactation ...
(Date:9/22/2017)... (PRWEB) , ... September 22, 2017 , ... ... book on the fallacy of an obligatory tithe, and the freedom experienced when ... is the creation of published author, Lysa M. Harrison. , Published by Christian ...
(Date:9/22/2017)... , ... September 22, 2017 , ... ... you brush more effectively even on the go. Their electric toothbrushes aggressively attack ... gum inflammation, with UV sanitizing technology. Combining leading edge Enke technology with a ...
(Date:9/22/2017)... ... 22, 2017 , ... Egg freezing and embryo freezing are ... a slight statistical advantage for live births, frozen eggs offer many advantages, depending ... undergoing medical treatment or who are concerned about the decline of their fertility ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for Medical ... p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device manufacturing ... The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a warning ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
(Date:9/5/2017)... LONDON , Sept. 5, 2017  Just 18 ... Valid Insight is pleased to announce the appointment of ... Tammy Wynne , Dominic Jones-Phillips and ... from industry. ... a team of market access writers. She has over ...
Breaking Medicine Technology: